Osteoclast

(redirected from Osteoclasts)
Also found in: Dictionary, Thesaurus, Medical.

osteoclast

[′äs·tē·ə‚klast]
(histology)
A large multinuclear cell associated with bone resorption.
(medicine)
A large surgical apparatus through which leverage can be exerted to effect osteoclasis.
McGraw-Hill Dictionary of Scientific & Technical Terms, 6E, Copyright © 2003 by The McGraw-Hill Companies, Inc.
The following article is from The Great Soviet Encyclopedia (1979). It might be outdated or ideologically biased.

Osteoclast

 

a cell that is involved in the destruction and resorption of bone tissue in vertebrate animals and man. An osteoclast contains from three to several dozen nuclei and a great many lysosomes, whose hydrolytic enzymes upon release from the osteoclasts resorb the mineral matrix of bone and calcified cartilage.

The Great Soviet Encyclopedia, 3rd Edition (1970-1979). © 2010 The Gale Group, Inc. All rights reserved.
References in periodicals archive ?
Thus, the activation of osteoclasts is triggered by the balance between RANKL and OPG (12-13).
Osteoimmunology and the influence of proinflammatory cytokines on osteoclasts. Biochem Med (Zagreb) 2013;23:43-63.
Comparison of osteoclastogenesis and resorption activity of human osteoclasts on tissue culture polystyrene and on natural extracellular bone matrix in 2D and 3D.
Since circulating monocytes have two fates, either apoptosis or differentiation, they suggested that decreasing apoptosis is a mechanism for increasing monocyte survival and thus migration and differentiation into osteoclasts [35].
However, some studies demonstrated that B cells and plasma cells in the bone microenvironment are significant sources of OPG [50-52], which is a neutralizing soluble decoy receptor that competes with RANKL, thus blocking the binding of RANKL and RANK, which eliminates the effect of RANKL on osteoclasts [53].
Oh et al., "CHMP5 controls bone turnover rates by dampening NF-kB activity in osteoclasts," The Journal of Experimental Medicine, vol.
It accomplished this by stimulating the proliferation of primitive bone marrow stem cells and their maturation into osteoblasts rather than other cells, such as bone-resorbing osteoclasts.
In bone tissue, PTH increases osteoclast formation and bone resorption by regulating the receptor activator of nuclear factor kappa B ligant (RANKL)/osteoprotegerin (OPG) expressed in osteoblasts.
The differentiated osteoclasts cause bone resorption by dissolving inorganic calcium hydroxyapatite in acidic conditions and organic bone matrix by MMPs and cathepsin K [23-25].
For inducing RAW264.7 cell fusion and differentiation into mature multinucleated cells (MNC) or osteoclasts, we cultured cells for 6 days in 35 ng/ml RANKL and stained them for detection of the marker protein tartrate-resistant acid phosphatase (TRAP) (Sigma-Aldrich, St.
AL is initiated by local inflammatory response to implant-derived wear particles that activate and recruit macrophages and osteoclasts, thereby leading to fibrous tissue interface and periprosthetic bone resorption.